Scilex Holding (SCLX) Other Non-Current Liabilities (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Other Non-Current Liabilities of $25.5 million for Q1 2026, down 53.38% year-over-year from $54.8 million in Q1 2025, and up 14578.74% on a QoQ basis from $174000.0 in Q4 2025.

Scilex Holding (SCLX) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Other Non-Current Liabilities for 7 consecutive years, with $25.5 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Other Non-Current Liabilities fell 53.38% year-over-year to $25.5 million; the TTM figure through Mar 2026 stood at $25.5 million (down 53.38% YoY), while the FY2025 annual figure was $174000.0, down 82.6% from the prior year.
  • Other Non-Current Liabilities came in at $25.5 million for Q1 2026 at Scilex Holding, up from $174000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $82.0 million in Q3 2025, with the low at $76788.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $11.9 million, with a median of $1.5 million recorded in 2023.
  • Across the five-year window, Other Non-Current Liabilities plunged 97.88% in 2022 and surged 8344.03% in 2023, its largest moves.
  • Year by year, Other Non-Current Liabilities stood at $1.2 million in 2022, then grew by 23.31% to $1.5 million in 2023, then tumbled by 34.12% to $1.0 million in 2024, then tumbled by 82.6% to $174000.0 in 2025, then jumped by 14578.74% to $25.5 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $25.5 million, $174000.0, and $82.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 25.54 Mn
Dec 31, 2025 174,000.00
Sep 30, 2025 81.98 Mn
Jun 30, 2025 165,000.00
Mar 31, 2025 54.79 Mn
Dec 31, 2024 1.00 Mn
Sep 30, 2024 11.45 Mn
Jun 30, 2024 187,000.00
Mar 31, 2024 6.94 Mn
Dec 31, 2023 1.52 Mn
Sep 30, 2023 2.10 Mn
Jun 30, 2023 6.57 Mn
Mar 31, 2023 6.48 Mn
Dec 31, 2022 1.23 Mn
Sep 30, 2022 1.16 Mn
Jun 30, 2022 1.23 Mn
Mar 31, 2022 76,788.00
Dec 31, 2021 35.70 Mn
Sep 30, 2021 4.86 Mn
Jun 30, 2021 3.69 Mn